Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules

Expert Review of Vaccines

Volumn 10, Issue 11, 2011, Pages 1621-1631

  Borrow, Ray ^a   Dagan, Ron ^b   Zepp, Fred ^c   Hallander, Hans ^d   Poolman, Jan ^e,f  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f CRUCELL HOLLAND BV   (Netherlands)

Author keywords

carrier induced epitopic suppression; conjugate vaccines; CRM 197; enhancement; Haemophilus influenzae type b; hepatitis B; interference; meningococcal vaccine; pneumococcal vaccine

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; DIPHTHERIA TOXOID CRM197; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B DIPHHERIA TOXOID VACCINE; HAEMOPHILUS INFLUENZAE TYPE B TETANUS TOXOID VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS DIPHTHERIA TOXOID CRM197 VACCINE; MENINGOCOCCUS TETANUS TOXOID VACCINE; MENINGOCOCCUS VACCINE; PEDIACEL; PNEUMOCOCCAL ANTIBODY; PNEUMOCOCCUS DIPHTHERIA TOXOID CRM197 VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYRIBOSYL RIBITOL PHOSPHATE ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE; BYSTANDER EFFECT; CARRIER INDUCED EPITOPIC SUPPRESSION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DIPHTHERIA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; HAEMOPHILUS INFECTION; HELPER CELL; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MEMORY CELL; MENINGOCOCCOSIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SEROLOGY; T LYMPHOCYTE; TETANUS;

ADJUVANTS, IMMUNOLOGIC; BACTERIAL PROTEINS; BACTERIAL VACCINES; DIPHTHERIA TOXOID; DRUG CARRIERS; DRUG INTERACTIONS; HUMANS; IMMUNIZATION SCHEDULE; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 80455126036     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.142     Document Type: Review

References (45)

1. Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa- Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev. Vaccines 7(1), 97-115 (2008). (Pubitemid 351357968)
2. Dagan R, Poolman J, Siegrist C. Glycoconjugate vaccines and immune interference: a review. Vaccine 28, 5513-5523 (2010).
3. Klein Klouwenberg P, Bont L. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin. Dev. Immunol. 2008, 628963 (2008).
4. Kitchin NRE, Southern J, Morris R et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus- Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch. Dis. Child 92, 11-16 (2007). (Pubitemid 46132925)
5. Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/ Hib vaccine. Vaccine 24, 215-219 (2006). (Pubitemid 41753009)
6. Tejedor JC, Moro M, Ruiz-Contreras J et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus- acellular pertussishepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 25, 713-720 (2006). (Pubitemid 44162129)
7. Schmitt H, Maechler G, Habermehl P et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol. 14, 426-434 (2007). (Pubitemid 46732554)
8. Knuf M, Szenborn L, Moro M et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr. Infect. Dis. J. 28, S97-S108 (2009).
9. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66, 2093-2098 (1998). (Pubitemid 28194107)
10. Dagan R, Goldblatt D, Maleckar JR, Yaïch M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect. Immun. 72, 5383-5391 (2004). (Pubitemid 39223427)
11. Peeters CC, Tenbergen-Meekes AM, Poolman JT, Beurret M, Zegers BJ, Rijkers GT. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59, 3504-3510 (1991).
12. Granoff DM, Holmes SJ, Belshe RB, Osterholm MT, McHugh JE, Anderson EL. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA 272, 1116-1121 (1994). (Pubitemid 24299345)
13. Shelly MA, Pichichero ME, Treanor JJ. Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults. Scand. J. Infect. Dis. 33, 542-544 (2001). (Pubitemid 32755349)
14. Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 11(Suppl. 1), S46-S51 (1993). (Pubitemid 23057250)
15. Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr. Infect. Dis. J. 12, 484-492 (1993). (Pubitemid 23173492)
16. Rennels M, King J, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23, 429-435 (2004). (Pubitemid 38621482)
17. Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299, 173-184 (2008).
18. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWYTT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27, 161-168 (2009).
19. Heath PT, McVernon J. The UK Hib vaccine experience. Arch. Dis. Child. 86, 396-399 (2002). (Pubitemid 34596646)
20. Moss SJ, Fenton AC, Toomey J et al. Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age. Clin. Vaccine Immunol. 17, 311-316 (2010).
21. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt H. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24, 4727-4736 (2006). (Pubitemid 43776787)
22. Tichmann-Schumann I, Soemantri P, Behre U et al. Immunogenicity and reactogenicity of four doses of diphtheriatetanus- three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 24, 70-77 (2005). (Pubitemid 40353319)
23. Zepp F, Knuf M, Heininger UJ et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22, 2226-2233 (2004). (Pubitemid 38626062)
24. Tichmann I, Preidel H, Grunert D et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 23, 3272-3279 (2005). (Pubitemid 40523120)
25. Reynolds D, Boisnard F, Thomas S, Mwawsi G, Grimprel E, Wysocki J. Immunogenicity and safety profile of Pediacel® compared with Infanrix®- IPV+Hib at 2,3 and 4 months of age, both co-administered with Prevenar®. Presented at: 27th Annual Meeting of the European Society for Paedatric Infectious Disease (ESPID). Brussels, Belgium, 9-13 June 2009.
26. Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 22, 397-402 (1994).
27. Käyhty H, Ahman H, Eriksson K, Sörberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J. 24, 108-114 (2005). (Pubitemid 40250767)
28. Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt H, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 26, 2545-2552 (2008).
29. Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 118, 878-887 (2010).
30. von Kries R, Böhm O, Windfuhr A. Haemophilus influenzae b-vaccination: the urgency for timely vaccination. Eur. J. Pediatr. 156, 282-287 (1997). (Pubitemid 27142148)
31. Diez-Dominigo F, Gurtman A, Bernaola E et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers receiving routine vaccinations in Spain. [Abstract]. Presented at: 27th Annual Meeting of the European Society for Paedatric Infectious Disease (ESPID). Brussels, Belgium, 9-13 June 2009.
32. Buttery JP, Riddell A, McVernon J et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 293, 1751-1758 (2005).
33. Griminez-Sanchez F, Kieninger D, Kueper K et al. Immunogenicity of DTaP-HBVIPV/ Hib combination vaccine antigens when given concomitantly with 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers. [abstract]. Presented at: 47th Annual Meeting of the IDSA. Philadelphia, PA, USA, 29 Ocotber-1 November 2009.
34. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 125, 866-875 (2010).
35. Esposito S, Tansey S, Thompson A et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin. Vaccine Immunol. 17, 1017-1026 (2010).
36. Goldblatt D, Southern J, Ashton L et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr. Infect. Dis. J. 29, 401-405 (2010).
37. Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine 26, 3142-3152 (2008).
38. Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine 24, 2057-2064 (2006). (Pubitemid 43255147)
39. Pace D. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. Curr. Opin. Mol. Ther. 11, 692-706 (2009).
40. Knuf M, Kieninger-Baum D, Habermehl P et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal erogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28, 744-753 (2010).
41. Southern J, Borrow R, Andrews N et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin. Vaccine Immunol. 16, 194-199 (2009).
42. Arístegui J, Dal-Ré R, Díez-Delgado J et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa- HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 21, 3593-3600 (2003).
43. Kilpi TM, Silfverdal SA, Nilsson L et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussishepatitis B-inactivated polio virus- Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum. Vaccin. 5, 18-25 (2009).
44. Silfverdal SA, Hogh B, Bergsaker MR et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr. Infect. Dis. J. 28, e276-e282 (2009).
45. Goldblatt D, Southern J, Ashton L et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25, 312-319 (2006).